HOW TO PLAY IT

Forbes - - TECHNOLOGY - BY JOHN DOBOSZ

Merid­ian Bio­science, based in cincin­nati, is a global seller of di­ag­nos­tic test kits for a host of mal­adies, in­clud­ing strep­to­coc­cus, c. dif­fi­cile, h. py­lori, mononu­cle­o­sis, food-borne dis­eases, res­pi­ra­tory in­fec­tions and other ar­eas such as par­a­sitol­ogy and stool anal­y­sis. merid­ian also sells pu­ri­fied reagents and prod­ucts used in drug de­vel­op­ment. rev­enue this year is ex­pected to grow 5.7% to $212.2 mil­lion, with earn­ings up 6% to $0.71 per share. The com­pany has been in busi­ness since 1977, and it has paid div­i­dends since 1990. With a quar­terly pay­out of $0.125 per share, merid­ian is good for a yield of 3%. shares have gained more than 16% since early may, but the stock still trades 18% be­low five-year av­er­age ra­tios of price-to-sales and price-to-book value. John Dobosz is the editor of forbes div­i­dend in­vestor and forbes Pre­mium in­come re­port.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.